CureGN

治愈GN

• 批准号: 10467455
• 负责人: BRENDA W GILLESPIE
• 金额: $ 14万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-23 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10467455
• 关键词: Ancillary Study; Antibodies; Autoantibodies; Biological Assay; Biological Markers; Biology; Blood specimen; Clinic; Clinical; Clinical Data; Clinical Research; Data Set; Diagnostic; Disease; Disease Marker; Focal Segmental Glomerulosclerosis; Funding; IGA Glomerulonephritis; Infrastructure; Kidney Diseases; Laboratories; Link; Measures; Membranous Glomerulonephritis; Monitor; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; Participant; Pathogenesis; Patients; Phospholipase A2; Prognosis; Renal glomerular disease; Research; Scientist; Serum; Therapeutic; Thrombospondins; Time; Translational Research; cohort; digital repositories; disease heterogeneity; ethnic diversity; improved; international center; kidney biopsy; receptor

ABSTRACT Cure Glomerulonephropathy (CureGN) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored, multi-center international consortium established in 2013 to study the natural history of glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy), understand their underlying biology, develop biomarkers to resolve disease heterogeneity, and ultimately improve therapeutic options. CureGN has made progress in: 1) establishing a large, ethnically diverse longitudinal observational cohort of glomerular disease patients; 2) creating a rich, well-curated clinical data set and linked biospecimens; 3) establishing the largest repository of digital kidney biopsies; and 4) an infrastructure that will facilitate translational and clinical research by core and ancillary study scientists. This supplemental funding request is to measure serum antibodies to M-type phospholipase A2 receptor (anti- PLA2R levels) and thrombospondin type I domain-containing 7A (THSD7A) from the existing biosamples of the CureGN membranous nephropathy participants. These biomarkers which were not widely clinically available at the time of CureGN launch have now been identified as key markers for disease pathogenesis, prognosis and therapeutic monitoring and are essential information for any study analyzing MN. CureGN will use the Mayo Clinic BioPharma Diagnostics central laboratory which routinely performs these assays for research and clinical purposes.

抽象的 Cure 肾小球肾病 (CureGN) 是国家糖尿病、消化和肾脏疾病研究所 (NIDDK) 赞助的多中心国际联盟于 2013 年成立，旨在研究自然历史 肾小球疾病（微小病变、局灶节段性肾小球硬化、膜性肾病、 和 IgA 肾病），了解其基础生物学，开发生物标志物来解决疾病 异质性，并最终改善治疗选择。 CureGN 在以下方面取得了进展：1）建立了 大型、种族多样化的肾小球疾病患者纵向观察队列； 2）创造财富， 精心策划的临床数据集和链接的生物样本； 3）建立最大的数字肾资源库 活检； 4）通过核心和辅助手段促进转化和临床研究的基础设施 研究科学家。 这项补充资金请求是为了测量 M 型磷脂酶 A2 受体（抗 PLA2R水平）和含有血小板反应蛋白I型结构域的7A（THSD7A）来自现有的生物样本 CureGN 膜性肾病参与者。这些生物标志物尚未广泛应用于临床 在 CureGN 推出时现已被确定为疾病发病机制、预后的关键标志物 和治疗监测，是任何分析 MN 的研究的重要信息。 CureGN 将使用 梅奥诊所生物制药诊断中心实验室定期执行这些分析以进行研究和 临床目的。